Toni M. Brand, Ph.D.
Affiliations: | 2014 | Cellular & Molecular Pathology | University of Wisconsin, Madison, Madison, WI |
Area:
Cell Biology, Oncology, PharmacologyGoogle:
"Toni Brand"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Deric L. Wheeler | grad student | 2014 | UW Madison | |
| (Investigations of nuclear HER family receptors in cancer and resistance to cetuximab therapy.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Brand TM, Iida M, Corrigan KL, et al. (2021) Retraction. Science Signaling. 14: eabn0168 |
| Brand TM, Iida M, Dunn EF, et al. (2019) Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer. Molecular Cancer Therapeutics. 18: 868 |
| Iida M, Brand TM, Campbell DA, et al. (2018) Correction: Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene |
| Brand TM, Iida M, Stein AP, et al. (2018) Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 6099 |
| Brand TM, Iida M, Luthar N, et al. (2018) Corrigendum to: "Nuclear EGFR as a molecular target in cancer" [Radiother Oncol 108 (2013) 370-77]. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology |
| Frazier NM, Brand T, Gordan JD, et al. (2018) Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. Oncogene |
| Leonard B, Brand TM, O'Keefe RA, et al. (2018) BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC. Cancer Research |
| Brand TM, Iida M, Corrigan KL, et al. (2017) The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Science Signaling. 10 |
| Brand T, Zeng Y, Leonard B, et al. (2017) Abstract 95: Targeting BRD4 overcomes cetuximab resistance in HNSCC Cancer Research. 77: 95-95 |
| Black NK, Iida M, Rodems TS, et al. (2017) Abstract 4176: Targeting TAM family members with antibody or small molecule inhibitors enhances therapeutic modalities of HNSCC Cancer Research. 77: 4176-4176 |